Interpace Biosciences®, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements (Tables)

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2019

Schedule of Financial Instrument Measured on Recurring Basis

The valuation methodologies used for the Company’s financial instruments measured on a recurring basis at fair value, including the general classification of such instruments pursuant to the valuation hierarchy, is set forth in the tables below:

	As of March 31, 2019				Fair Value Measurements
	Carrying		Fair		As of March 31, 2019
	Amount		Value		Level 1		Level 2		Level 3
	(unaudited)
Liabilities:
Contingent consideration:
Asuragen ⁽¹⁾	$	3,136	$	3,136	$	-	$	-	$	3,136
Other long-term liabilities:
Warrant liability ⁽²⁾		358		358		-		-		358
	$	3,494	$	3,494	$	-	$	-	$	3,494

	As of December 31, 2018				Fair Value Measurements
	Carrying		Fair		As of December 31, 2018
	Amount		Value		Level 1		Level 2		Level 3
Liabilities:
Contingent consideration:
Asuragen ⁽¹⁾	$	3,127	$	3,127	$	-	$	-	$	3,127
Other long-term liabilities:
Warrant liability ⁽²⁾		361		361		-		-		361
	$	3,488	$	3,488	$	-	$	-	$	3,488

⁽¹⁾⁽²⁾See Note 8, Accrued Expenses and Long-Term Liabilities

Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation

A roll forward of the carrying value of the Contingent Consideration Liability and the Underwriters’ Warrants to March 31, 2019 is as follows:

								Cancellation		Adjustment
								of Obligation/		to Fair Value/
	December 31, 2018		Payments			Accretion		Conversions Exercises		Mark to Market			March 31, 2019
	(unaudited)
Asuragen	$	3,127	$	(120	)	$	129	$	-	$	-		$	3,136

Underwriters Warrants		361		-			-		-		(3	)		358
	$	3,488	$	(120	)	$	129	$	-	$	(3	)	$	3,494